Litigation Details for Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc. (D. Del. 2013)

Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc. (D. Del. 2013)

Docket		Date Filed	2013-10-08
Court	District Court, D. Delaware	Date Terminated	2019-09-05
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	ACTAVIS LABORATORIES UT INC.
Patents	6,159,498; 6,488,963; 7,579,019; 8,603,514
Attorneys	David P. Dalke
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc. (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-08				External link to document

Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc., 1:13-cv-01674: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Reckitt Benckiser Pharmaceuticals Inc. sued Watson Laboratories Inc. in the U.S. District Court for the District of Delaware over Watson’s abbreviated new drug application for a generic version of Suboxone sublingual film, a buprenorphine/naloxone product used to treat opioid dependence. The case was part of Reckitt Benckiser’s effort to protect its film formulation against generic entry under the Hatch-Waxman Act.

The dispute centered on formulation and drug-delivery patents rather than the basic pharmacology of buprenorphine or naloxone. The case was later affected by Reckitt’s broader divestiture and restructuring of its pharmaceutical business, including the transfer of Suboxone-related assets to Indivior.

What was Reckitt Benckiser v. Watson about?

Reckitt Benckiser alleged that Watson’s ANDA product would infringe patents covering Suboxone sublingual film. Watson’s filing of a Paragraph IV certification gave Reckitt a statutory basis to bring an infringement action under 35 U.S.C. § 271(e)(2).

Case element	Detail
Case	Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:13-cv-01674
Plaintiff	Reckitt Benckiser Pharmaceuticals Inc.
Defendant	Watson Laboratories Inc., later associated with Actavis
Product	Generic buprenorphine/naloxone sublingual film
Reference product	Suboxone sublingual film
Regulatory pathway	ANDA under the Hatch-Waxman Act
Core dispute	Patent infringement and validity
Technology	Sublingual film composition and delivery system
Commercial issue	Timing and conditions of generic Suboxone film entry

The case did not challenge the underlying approval of buprenorphine/naloxone as an opioid-dependence treatment. It addressed whether Watson could obtain FDA approval and market a competing film product before expiration of the asserted patents.

What patents protected Suboxone sublingual film?

The principal patent family associated with the litigation included U.S. Patent No. 8,496,965 and U.S. Patent No. 8,603,514. These patents covered aspects of the Suboxone film dosage form, including the combination of active ingredients with film-forming and mucoadhesive materials.

U.S. Patent No. 8,496,965

U.S. Patent No. 8,496,965 was directed to pharmaceutical compositions for treating opioid dependence. The patent covered formulations containing buprenorphine and naloxone in a film dosage form, with claims directed to composition and delivery characteristics. It issued in 2013 and was part of the patent protection asserted against generic Suboxone film applicants.

U.S. Patent No. 8,603,514

U.S. Patent No. 8,603,514 concerned a drug-delivery system using a dissolvable or erodible film. Its claims addressed the structure and composition of the delivery system, including the incorporation of active pharmaceutical ingredients into a film suitable for administration through the oral mucosa.

The asserted claims were commercially important because a generic applicant could avoid infringement of a broad active-ingredient patent by changing the product’s composition, but it would face a more difficult design-around problem if the patent claims covered the film architecture or delivery mechanism.

What was the Hatch-Waxman basis for the lawsuit?

Watson’s ANDA included a Paragraph IV certification asserting that the relevant patents were invalid, unenforceable, or would not be infringed by Watson’s proposed product. Reckitt’s lawsuit triggered the 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and later court action.

The litigation therefore had two parallel tracks:

1. Patent adjudication in the Delaware district court.
2. FDA review of Watson’s ANDA, subject to the statutory stay and any settlement or court order affecting approval.

A Paragraph IV certification is commercially significant even before trial. It permits the generic applicant to challenge the branded company’s patents while creating potential 180-day first-filer exclusivity if the applicant is the first qualifying ANDA filer.

What was the litigation timeline?

Date or period	Event
2013	Reckitt Benckiser filed the Delaware patent action against Watson.
2013-2014	The parties litigated infringement, validity, and procedural issues concerning Watson’s ANDA product.
2014	Reckitt’s pharmaceutical business was separated from the broader consumer-health operations.
2014 onward	Suboxone-related rights and litigation interests became associated with Indivior.
Later period	Suboxone film patent disputes continued in separate litigation involving Indivior and other generic applicants.

The 2013 case should be distinguished from later Suboxone matters involving Indivior, Dr. Reddy’s Laboratories, Alvogen, Sandoz, Teva, and other generic manufacturers. Later cases addressed continuation patents, antitrust allegations, product switching, and separate ANDA filings.

How strong was Reckitt’s patent estate?

Reckitt’s patent position was strongest where the asserted claims captured the product’s film-delivery architecture rather than only the active ingredients.

Strengths

• The patents targeted a commercially differentiated dosage form.
• The film formulation combined buprenorphine and naloxone in a product designed for sublingual administration.
• Film-delivery claims created potential barriers to a generic applicant seeking to copy the reference product closely.
• The Orange Book-listed patents could delay FDA approval through the Hatch-Waxman stay.

Weaknesses

• Formulation patents are vulnerable to written-description, enablement, obviousness, and claim-construction challenges.
• A generic company may avoid infringement by modifying polymer selection, ingredient ratios, film thickness, dosing geometry, or manufacturing conditions.
• Continuation patents can extend litigation exposure but may face double-patenting and obviousness-type challenges.
• A patent covering a product characteristic must be mapped carefully to the ANDA formulation, manufacturing process, and labeling.

The estate had greater strategic value as a portfolio than as a single patent. A generic applicant could challenge individual claims, but multiple composition, delivery, and method-of-use patents increased the cost and timing risk of entry.

What was the FDA and Orange Book status?

Suboxone sublingual film was approved by the FDA as a prescription product containing buprenorphine and naloxone. The product was approved for opioid dependence treatment and was marketed in multiple dosage strengths.

The relevant patent strategy relied on Orange Book listings and Paragraph IV enforcement. Orange Book-listed patents can support a statutory stay of ANDA approval, but the listing must meet FDA requirements and the patent must claim the approved drug or an approved method of use. Patents directed solely to manufacturing processes generally do not create the same Orange Book-based approval barrier.

Because the case involved a film formulation, the commercial dispute focused on whether Watson’s proposed product would fall within composition and delivery claims associated with the approved Suboxone film.

Did Watson obtain a generic launch date?

The public record for this individual civil action does not establish a judicially ordered generic launch date comparable to a final judgment after trial. The commercial timing of Watson’s product must be analyzed separately from the filing date and from later agreements involving Actavis or Indivior.

A later settlement or license involving a corporate successor does not automatically establish the terms of the 2013 case. Hatch-Waxman settlements may include:

• A licensed entry date;
• An authorized-generic arrangement;
• Supply or distribution rights;
• Restrictions on product development;
• A covenant not to sue;
• Resolution of separate patent families.

The relevant entry date must therefore be taken from the operative settlement, dismissal order, or later FDA approval record, not inferred from the initial complaint.

What litigation affected Suboxone after the Watson case?

The Suboxone patent estate generated later litigation involving Indivior after Reckitt’s pharmaceutical business was separated. Those cases included challenges to patents covering Suboxone film, including later-issued continuation patents.

The later disputes had three principal themes:

Patent litigation

Generic manufacturers challenged the validity and enforceability of patents covering Suboxone film. Issues included obviousness, written description, anticipation, claim construction, and infringement.

Product-switching and antitrust litigation

Indivior faced allegations that it shifted the market from Suboxone tablets to film before generic tablet competition could develop. Those claims were separate from the direct ANDA infringement cases and focused on market conduct rather than only patent scope.

Settlement scrutiny

The Federal Trade Commission and private plaintiffs examined certain pharmaceutical patent settlements for potential anticompetitive effects. A settlement’s existence did not establish liability, but settlement terms could affect generic entry, authorized-generic competition, and the effective duration of brand protection.

How did Suboxone film compare with Suboxone tablets?

Issue	Suboxone tablets	Suboxone film
Dosage form	Sublingual tablet	Sublingual film
Main commercial advantage	Earlier dosage form	Greater product differentiation
Patent focus	Composition and use patents	Film composition, delivery system, and formulation patents
Generic design-around	Often based on tablet composition	May require changes to film structure and manufacturing
Regulatory issue	ANDA for tablet	ANDA for film
Litigation exposure	Earlier patent challenges	Later continuation and formulation disputes

The transition from tablets to film increased the importance of formulation patents. It also created a potential product-life-cycle strategy by moving demand toward a dosage form with a separate patent portfolio.

What generic-entry risks existed?

The principal generic-entry risks were:

1. Paragraph IV litigation risk. Watson’s challenge placed patent validity and infringement directly before the Delaware court.
2. Patent expiration risk. The most commercially important protection depended on the expiration dates of the asserted patent family, including any patent-term adjustment or pediatric exclusivity.
3. Design-around risk. Watson could seek approval for a film formulation that avoided specific composition or delivery limitations.
4. Settlement risk. A confidential or partially disclosed settlement could permit entry earlier than the full patent term.
5. Successor-company risk. Changes from Reckitt Benckiser to Indivior complicated ownership, enforcement, and interpretation of later agreements.
6. Regulatory substitution risk. FDA approval of competing buprenorphine/naloxone products could reduce the practical value of patent exclusivity even before full generic film substitution.

What was the commercial significance of the case?

Suboxone was a major product in the opioid-dependence-treatment market. Patent protection for the film product affected revenue retention, product-switching strategy, generic substitution, and the value of Reckitt’s pharmaceutical business before its separation.

The case had greater commercial significance than a routine ANDA action because the film product was a replacement and extension of the earlier tablet franchise. Protecting the film formulation supported continued branded sales after tablet competition increased.

The financial exposure depended on:

• Annual Suboxone film sales;
• The share of prescriptions converted from tablets to film;
• The number of approved generic competitors;
• The timing of first generic entry;
• Whether the generic entered through a settlement license or after patent invalidation;
• The availability of an authorized generic.

Key Takeaways

• Reckitt Benckiser sued Watson in Delaware over a generic Suboxone sublingual film ANDA.
• The case focused on formulation and drug-delivery patents, principally U.S. Patent Nos. 8,496,965 and 8,603,514.
• Watson’s Paragraph IV certification created a Hatch-Waxman infringement action and potential FDA approval stay.
• The commercial value of the patents arose from protection of the film dosage form, not merely buprenorphine/naloxone as active ingredients.
• Later Suboxone litigation involving Indivior should be analyzed separately from the 2013 Reckitt-Watson docket.
• Generic entry timing cannot be established solely from the complaint; it depends on the operative disposition, settlement, FDA approval record, and later patent proceedings.

FAQs About Reckitt Benckiser v. Watson

Did the case involve Suboxone tablets or film?

It involved the generic version of Suboxone sublingual film. The litigation should not be conflated with earlier tablet-related patent disputes.

Was Watson’s product approved by the FDA?

The case concerned an ANDA seeking FDA approval. Approval timing depended on the Paragraph IV litigation, the statutory stay, and any later settlement or regulatory action.

Did the case establish that Suboxone film patents were valid?

A filing or settlement does not establish patent validity. Validity requires a final judgment or an enforceable adjudicated resolution addressing the specific claims.

Did Reckitt Benckiser remain the patent owner throughout the litigation?

Suboxone-related pharmaceutical assets later became associated with Indivior after the separation of Reckitt’s pharmaceutical business. Ownership and enforcement rights must be determined from the relevant assignment and corporate-transaction records.

Are Suboxone film patents still relevant to generic competition?

Yes. Later continuation patents and separate ANDA cases continued to affect generic competition, even where individual earlier patents expired, were invalidated, or were resolved through settlement.

References

1. U.S. District Court for the District of Delaware. (2013). Reckitt Benckiser Pharmaceuticals Inc. v. Watson Laboratories Inc., No. 1:13-cv-01674. PACER docket records.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,496,965: Pharmaceutical compositions for treating opioid dependence.

4. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,603,514: Drug delivery system.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

6. Hatch-Waxman Act, 35 U.S.C. § 271(e)(2).